Citations

Clear

3057 citation(s) found for "Cd, Johnson".

324 | RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA
Wang, Y., Nedved, Adrienne, Fahmawi, Suhib, Lutfi, Forat , Johnson, Paul C., Dong, Ning , Hill, Brian T. , Nowakowski, G., Larson, Melissa C. , Wang, Jun , Karmali, Reem , Lei, Matthew , Johnson, P. C., Moustafa, Muhamad Alhaj , Chavez, Julio C , Brooks, Taylor , Muñoz, Javier , Hu, Yifei , Riedell, Peter A. , Godbole, S., Sawalha, Yazeed , Rhodes, Joanna

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_324 Get It

450 | 5‐5‐5 ABRT (ADAPTIVE BRIDGING RADIATION THERAPY)—ARTIFICIAL INTELLIGENCE ENTERS THE CAR (‐T) IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS
Ababneh, H., Ng, Andrea K. , Walburn, Tyler , Johnson, P. C., Bredtfeld, Jeremy, Leeman, Jonathan E. , Barnes, J. , Takvorian, Ronald W., Frigault, M., Patel, Chirayu G. , Wan, Juefeng , Zhu, Lin L. , Bobić, Mislav , Soumerai, Jacob D. , Abramson, J., Pursley, J.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_450 Get It

572 | PATIENT‐REPORTED OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS TREATED WITH EPCORITAMAB: OVERALL AND SUBGROUP ANALYSIS BY BASELINE SYMPTOM BURDEN
Johnson, P. C., Nsiah, Irene , Ding, Zhijie , Mutebi, Alex , Patah, Poliana, Favaro, Enrico, Dueck, Amylou C. , Ghione, Paola , Major, Ajay , Wang, Anthony , Alshreef, Abualbishr , Yu, Jovian , Favaro, E., Jurczak, Wojciech

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_572 Get It

Systemic Neisseria sicca Infection Associated With Ravulizumab Therapy in Myasthenia Gravis
McCoyle, McKenzye M. DeHart , Muzyka, Iryna M., Muley, Suraj , Smith, Benn, Johnson, Alec, Nagarakanti, Sandhya R., Smith, Benn E., Johnson, Alec, Nagarakanti, Sandhya

Mayo Clinic

Muscle & Nerve | June 13, 2025 | Volume: 72 | Issue: 4 | Pages: 676-677

10.1002/mus.28454 | PMID 40511556 Get It

The impact of body size, prior care quality, and weight gain on health care utilization during the COVID‐19 pandemic
Phelan, Sean M. , Barwise, Amelia , Akambase, Jay‐Sharee P., Johnson, Matthew G. , Huang, Lily , Allyse, Megan , Phelan, S M , Allyse, Megan A , Barwise, Amelia K , Philip, Samantha R.

Mayo Clinic

Clinical Obesity | June 12, 2025 | Volume: 15 | Issue: 5 | Pages: No page available

10.1111/cob.70019 | PMID 40484636 Get It

SummaryThe goal of this study was to ascertain the effect of patient body size on clinic‐ or patient‐delayed health care during the COVID‐19 pandemic and factors predicting delay. Primary survey data were collected in August 2021 from 3593 individuals living within the communities near Mayo Clinic facilities in Minnesota, Wisconsin, Arizona, and Florida. More people who identified with the higher‐weight BMI categories reported having their care appointments cancelled (62.3%) compared to those who identified with normative weight (38.0%) or underweight (47.7%; p < .001) and reported more frequently delaying their own care (67.9%) relative to those who identified with normative weight (47.0%) or underweight (62.3%; p < .001). Higher‐weight people were more likely than others to report delay was due to not knowing where to get care (UW: 5.6%, NW: 3.5%, HW: 7.0%, pchi‐square < .001), worrying about weight‐based judgement (UW: 2.1%, NW: 2.1%, HW: 4.5%, pchi‐square < .001), and fearing discrimination (UW: 2.9%, NW: 2.4%, HW: 5.5%, pchi‐square < .001). There was no difference across groups in delay due to fear of COVID‐19 exposure. Weight gain was associated with care delay in higher‐weight and normative weight groups. Having experienced more patient‐centred care pre‐COVID was associated with less care delay in the normative weight group, but more care delay in other groups. Higher‐weight people were more likely to have their care delayed by health care providers and to delay care themselves. Patient weight gain and concerns about discrimination and judgement about weight gain may have driven the delay of needed care during COVID‐19.
Enhanced analytic methodology enables postmortem diagnosis of hereditary AApoAI amyloidosis
Hasadsri, Linda , Dasari, Surendra , Theis, Jason D. , Vrana, Julie A. , Johnson, M. L., Theis, Jeanne L. , Johnson, Mckinzie, Driscoll, Meghan , McPhail, Ellen Darcy , Rech, Karen L.

Mayo Clinic

Amyloid | June 12, 2025 | Volume: 32 | Issue: 4 | Pages: 361-363

10.1080/13506129.2025.2515938 | PMID 40503944 Get It

Successful Utilization of Organ Care System in Three Pediatric Heart Transplant Recipients
Yu, Liwei , Johnson, Jonathan N. , Daly, Richard C., Dearani, Joseph A. , Stephens, Elizabeth H. , Villavicencio, Mauricio A. , Reynolds, F.A., Ameduri, Rebecca , Reynolds, Frank A, Dearani, Joseph A.

Mayo Clinic

Pediatric Transplantation | June 11, 2025 | Volume: 29 | Issue: 5 | Pages: No page available

10.1111/petr.70114 | PMID 40495294 Get It

ABSTRACT Introduction Improving organ preservation is essential for expanding the donor pool and enhancing outcomes for pediatric transplant recipients. This report presents three pediatric patients who received donor hearts preserved using the Organ Care System (OCS). All donor hearts were prepared, placed, and monitored on OCS according to standard protocols. Heart function and myocardial edema were visually assessed during monitoring. Case Reports Patient 1: A 17‐year‐old female patient with hypertrophic cardiomyopathy utilized OCS technology due to donor distance. She experienced an uncomplicated post‐transplant course and was discharged on post‐transplant day 10. Patient 2: A 14‐year‐old male patient with complex congenital heart disease, palliated with Fontan circulation, underwent orthotopic heart transplantation (OHT) with OCS support due to both the complexity of the procedure and donor heart distance. His post‐transplant course was complicated by a revision of the ascending aorta anastomosis and prolonged milrinone infusion for diastolic dysfunction. He was discharged on post‐transplant day 31. Patient 3: A 16‐year‐old male patient with hypoplastic left heart syndrome, also palliated with Fontan circulation, underwent OHT using OCS technology due to the complexity of the surgical procedure. His post‐transplant recovery was unremarkable, and he was discharged on post‐transplant day 15. Conclusions All three pediatric patients demonstrated favorable short‐term outcomes using OCS technology. The OCS system facilitated shorter ischemic times despite the need for extended transport distances or complex surgical procedures. However, further studies with larger patient cohorts and longer follow‐up are needed to better understand the long‐term impact of OCS on pediatric heart transplantation outcomes.
The Impact of Social Determinants of Health on the Severity of Symptoms at Presentation and Discharge Disposition in Patients Undergoing Surgical Treatment of Cervical Myelopathy
Francois, Hendrick , Boateng, Atta , Jiang, Kelly , Johnson, Sarah E. , Smith, Kitara, Azad, Tej D., Ashayeri, Kimberly , Johnson, Sarah, Theodore, Nicholas , Weber-Levine, Carly , Mahapatra, Smruti , Davidar, A. Daniel , Hersh, Andrew M. , Alomari, Safwan , Bhimreddy, Meghana , Azad, Tej Deepak , Theodore, Nicholas

Mayo Clinic

Neurosurgery | June 9, 2025 | Volume: 98 | Issue: 1 | Pages: 211-220

10.1227/neu.0000000000003557 | PMID 40488526 Get It

BACKGROUND AND OBJECTIVES: Social determinants of health (SDOH), such as education, insurance, race, and income, significantly affect a patient's medical care and surgical outcomes. Additional studies characterizing the impact of SDOH on patients undergoing spine surgery are needed. Accordingly, this study evaluates the impact of SDOH on severity of symptoms at presentation and discharge disposition in patients undergoing surgical treatment of cervical myelopathy. METHODS: A retrospective single-center study identified adult patients undergoing surgical intervention for cervical myelopathy between 2016 and 2020. Cohort characteristics were collected from patient medical records. The t -test, Wilcoxon rank-sum, analysis of variance, Kruskal-Wallis, and χ 2 tests were used to compare variables when appropriate. Multivariable linear and logistic regression analyses were conducted for modified Japanese Orthopaedic Association (mJOA) and discharge disposition. All statistical analysis was performed in MATLAB R2022b (MathWorks, Natick, MA). RESULTS: A total of 480 patients were included in the study with a male predominance of n = 281 (59%) and a mean age of 62 ± 13 years. Racial demographics included 64% White (n = 308) and 36% Non-White (n = 172) patients. On univariable analysis, mJOA at presentation was significantly associated with employment status ( P < .01), annual income ( P < .01), education level ( P < .01), and insurance status ( P = .03). On multivariable analysis, annual income and education level continued to be significant predictors of presenting mJOA. On univariable analysis, discharge disposition was associated with body mass index ( P = .01), mJOA at presentation ( P < .01), employment status ( P = .05), annual income ( P < .01), education level ( P < .01), insurance ( P < .01), approach ( P < .01), and length of stay ( P < .01). On multivariable analysis, mJOA at presentation, education level, insurance, and approach continued to be significant predictors of discharge disposition. CONCLUSION: SDOH affect the severity of symptoms at presentation and discharge disposition in patients undergoing surgery for cervical myelopathy. Understanding these dynamics and uncovering additional SDOH are critical for enhancing surgical care and achieving equitable healthcare outcomes.
The Effectiveness of Sacubitril/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis
Eshak, Nouran , Abdelnabi, Mahmoud , Quillen, Jaxon , Pham, Michael M. , Hentz, Joseph G. , Pham, Micheal, Quillen, Jaxon K , Nagaraja, Vivek

Mayo Clinic

Journal of Clinical Medicine | June 9, 2025 | Volume: 14 | Issue: 12 | Pages: 4054

10.3390/jcm14124054 | PMID 40565799 Get It

Introduction: Cardiac involvement in patients with systemic sclerosis (SSc) can present variably from being asymptomatic to manifesting with heart failure, conduction abnormalities, pulmonary hypertension, and pericardial effusion. Symptomatic cardiac involvement portends a poor prognosis and worse overall survival. Sacubitril/valsartan (SV), an angiotensin receptor neprilysin inhibitor, has been shown to significantly reduce hospitalization rates and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the effects of SV treatment in patients with SSc and heart failure. Methods: A retrospective analysis of patients with SSc was conducted using an electronic data capture tool. Patients with SSc treated with SV between January 2015 and August 2023 were identified. Comprehensive clinical phenotyping and longitudinal data analysis were performed to characterize the sub-type of patients and evaluate clinical outcomes, including hospitalizations and mortality, laboratory markers, and echocardiographic findings. Results: Twenty-four patients with SSc were treated with SV for a mean duration of 20.6 months. HFrEF was the primary indication for SV use in 91% of patients, primarily due to non-ischemic cardiomyopathy (87.5%). There was a significant reduction in systolic blood pressure from 128 mmHg to 114 mmHg (p < 0.001) and NT-proBNP levels from 15,130 pg/mL to 5082 pg/mL (p = 0.046). In the 19 patients with baseline and follow-up echocardiograms, there was a significant improvement in LVEF from 40.3% to 47.7% (p = 0.014). Hypotension was a common side effect leading to discontinuation of SV (n = 4, 16.7%). Serum creatinine had trends of improvement (1.9 mg/dL to 1.3 mg/d), though it did not reach statistical significance (p = 0.057). Conclusions: This study showed that SV effectively improved cardiac symptoms and function in patients with SSc presenting with HFrEF. Further prospective studies are needed to confirm these findings and explore the role of SV in the treatment of other manifestations of SSc.
American Epilepsy Society/International League Against Epilepsy-North America Joint Task Force for Epilepsy Health Care Disparities in the United States
Kapur, Jaideep , Theodore, William, Clarke, Dave, Etienne, Mill, Gutierrez, Camilo , Jobst, Barbara C. , Johnson, Emily L. , Joshi, Sucheta, Kiriakopoulos, Elaine T. , Labiner, David M. , Lado, Fred A., Lowenstein, Daniel H. , Parko, Karen, Riker, Ellen, Poduri, Annapurna, Shellhaas, Renée A. , Sirven, Joseph I., Skjei, Karen, Stern, John M., Welty, Timothy E., Eickmeyer, Adam B., Strickland, Shawna L , Johnson, Emily L , Lekoubou, Alain , Lowenstein, Daniel , Shellhaas, Renée A , Strickland, Shawna L , Kapur, Jaideep , Jobst, Barbara , Theodore, William, Clarke, Dave, Etienne, Mill, Gutierrez, Camilo , Joshi, Sucheta, Kiriakopoulos, Elaine T. , Labiner, David M. , Lado, Fred A., Parko, Karen, Riker, Ellen, Poduri, Annapurna, Sirven, Joseph I., Skjei, Karen, Stern, John M., Welty, Timothy E.

Mayo Clinic

Epilepsy Currents | June 9, 2025 | Volume: 26 | Issue: 2 | Pages: 99-107

10.1177/15357597251342227 | PMID 40502806 Get It

Numerous factors including social determinants of health, knowledge gaps, economic challenges, workforce limitations, and health system deficiencies are associated with significant disparities in access to health care services and health outcomes for people with epilepsy (PWE). The American Epilepsy Society (AES) and the International League Against Epilepsy—North America (ILAE-NA) established a joint task force to explore and develop recommendations to address health care disparities experienced by PWE. The task force gathered foundational knowledge through meetings, public and patient organization comments and discussions to develop consensus recommendations. We enumerate the recommendations and discuss the rationale behind them to reduce disparities in epilepsy care through comprehensive research, inclusive clinical practices, robust advocacy, and targeted educational initiatives. While our recommendations are focused on the United States, we acknowledge that similar barriers and limitations exist for PWE globally and that these also need to be addressed within their local domains and with attention to unique factors therewithin.